MaxCyte (NASDAQ:MXCT) Raised to “Hold” at Wall Street Zen

MaxCyte (NASDAQ:MXCT) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

MXCT has been the subject of several other research reports. Stifel Nicolaus reduced their price objective on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th. BTIG Research set a $6.00 price objective on shares of MaxCyte and gave the stock a “buy” rating in a report on Wednesday, March 12th.

MaxCyte Stock Performance

NASDAQ MXCT opened at $2.18 on Friday. MaxCyte has a twelve month low of $2.10 and a twelve month high of $5.26. The stock has a market cap of $231.99 million, a price-to-earnings ratio of -6.41 and a beta of 1.27. The firm’s 50 day moving average price is $2.47 and its two-hundred day moving average price is $3.43.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The firm had revenue of $10.39 million for the quarter, compared to analysts’ expectations of $9.05 million. On average, research analysts forecast that MaxCyte will post -0.42 EPS for the current fiscal year.

Institutional Trading of MaxCyte

A number of institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC grew its holdings in shares of MaxCyte by 25.9% in the 4th quarter. SG Americas Securities LLC now owns 47,805 shares of the company’s stock valued at $199,000 after buying an additional 9,836 shares during the period. Chevy Chase Trust Holdings LLC raised its holdings in shares of MaxCyte by 0.6% in the 4th quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company’s stock valued at $5,574,000 after purchasing an additional 7,781 shares during the period. Rhumbline Advisers raised its holdings in shares of MaxCyte by 1.6% in the 4th quarter. Rhumbline Advisers now owns 153,655 shares of the company’s stock valued at $639,000 after purchasing an additional 2,402 shares during the period. Valmark Advisers Inc. raised its holdings in shares of MaxCyte by 2.2% in the 4th quarter. Valmark Advisers Inc. now owns 115,654 shares of the company’s stock valued at $481,000 after purchasing an additional 2,478 shares during the period. Finally, Rice Hall James & Associates LLC bought a new stake in shares of MaxCyte in the 4th quarter valued at about $1,098,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.